Comparing Inozyme Pharma (NASDAQ:INZY) and Yumanity Therapeutics (NASDAQ:YMTX)

Inozyme Pharma (NASDAQ:INZY) and Yumanity Therapeutics (NASDAQ:YMTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Inozyme Pharma and Yumanity Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inozyme Pharma 0 0 1 0 3.00
Yumanity Therapeutics 0 0 2 0 3.00

Inozyme Pharma presently has a consensus target price of $23.00, indicating a potential upside of 241.25%. Yumanity Therapeutics has a consensus target price of $37.00, indicating a potential upside of 1,265.31%. Given Yumanity Therapeutics’ higher probable upside, analysts clearly believe Yumanity Therapeutics is more favorable than Inozyme Pharma.

Risk & Volatility

Inozyme Pharma has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500. Comparatively, Yumanity Therapeutics has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500.

Insider & Institutional Ownership

73.9% of Inozyme Pharma shares are held by institutional investors. Comparatively, 37.4% of Yumanity Therapeutics shares are held by institutional investors. 11.3% of Inozyme Pharma shares are held by insiders. Comparatively, 12.5% of Yumanity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Inozyme Pharma and Yumanity Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Inozyme Pharma N/A -34.30% -31.90%
Yumanity Therapeutics -605.00% -147.18% -73.43%

Earnings and Valuation

This table compares Inozyme Pharma and Yumanity Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Inozyme Pharma N/A N/A -$56.42 million N/A N/A
Yumanity Therapeutics $6.90 million 4.05 -$57.49 million N/A N/A

Inozyme Pharma has higher earnings, but lower revenue than Yumanity Therapeutics.

Summary

Inozyme Pharma beats Yumanity Therapeutics on 6 of the 10 factors compared between the two stocks.

About Inozyme Pharma

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

About Yumanity Therapeutics

Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. It is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. Its platform is based on technology, which enables the rapid screening for novel disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which usually results from an aberrant accumulation of misfolded proteins in the brain. The company was founded by Susan Lindquist and Tony Coles in December 2014 and is headquartered in Boston, MA.

Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.